Monopar Therapeutics (MNPR) vs Rezolute (RZLT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Monopar Therapeutics (MNPR) has outperformed Rezolute (RZLT) over the past year, losing 24.6% versus a loss of 60.1%. Over five years, MNPR leads with a +184.5% price change compared with -26.9% for RZLT. Monopar Therapeutics is the larger company by market cap ($467.6 million vs $465.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MNPR | RZLT |
|---|---|---|
| Share price | $69.00 | $3.92 |
| Market cap | $467.60M | $465.58M |
| 1-day change | -1.84% | -6.67% |
| YTD return | +5.67% | +66.10% |
| 1-year return | -24.64% | -60.12% |
| 5-year return | +184.54% | -26.87% |
| EPS (TTM) | $-2.44 | $-0.76 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | — |
| Net income (latest FY) | $-13.72M | $-77.60M |
| 52-week high | $124.82 | $11.17 |
| 52-week low | $50.07 | $1.07 |
| Distance from 52-week high | -44.72% | -64.89% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +88.65% | +175.51% |
| Average volume | 151.83K | 1.66M |
| Shares outstanding | 6.78M | 118.77M |
| Employees | 22 | 63 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MNPR has outperformed RZLT by 35.5 percentage points over the past year.
About Monopar Therapeutics
MNPR stock →Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
About Rezolute
RZLT stock →Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI.
Health Care · Biotechnology: Pharmaceutical Preparations · 63 employees
MNPR vs RZLT FAQ
Which is bigger, Monopar Therapeutics or Rezolute?
Monopar Therapeutics (MNPR) is larger, with a market capitalization of $467.60M compared with $465.58M for Rezolute (RZLT).
Which stock has performed better over the past year, MNPR or RZLT?
MNPR returned -24.64% over the past 12 months, compared with -60.12% for RZLT (price return, excluding dividends). Past performance does not predict future results.
Are Monopar Therapeutics and Rezolute in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.